Status: Recruiting
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
Participants needed: 54
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Veronika BachanovaUpdated: Jun 12, 2026Locations: 6
Eligibility criteria
Written informed consent and HIPAA authorization for release of personal health... [+16]
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use whi... [+11]